Protagonist Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Protagonist Therapeutics submitted NDAs for Icotyde and rusfertide in 2025, expanded its pipeline, and ended the year with $646 million in cash despite a net loss.
NASDAQ
10-K: Protagonist Therapeutics Reports Positive Phase 3 Results and Significant Financial Gains in 2024
Protagonist Therapeutics highlights positive Phase 3 results for Icotrokinra, a worldwide license and collaboration agreement for Rusfertide with Takeda, and a strong cash position at the end of 2024.
NASDAQ
Protagonist Therapeutics' 2023 10-K filing highlights the progress of their lead drug candidates, rusfertide for blood disorders and JNJ-2113 for inflammatory diseases, along with a new collaboration with Takeda.